Introduction
============

The placebo effect is a common phenomenon in clinical practice and clinical trials for various types of diseases, as shown by Beecher.[@b1-rru-5-083] Although the definition of placebo effect varies considerably in the literature, Kaptchuk defined it as the effect seen in patients who have received an intervention that is believed to lack a specific action.[@b2-rru-5-083] Ernst and Resch[@b3-rru-5-083] and Ernst[@b4-rru-5-083] postulated the concepts of "true" and "perceived" placebo effects. The perceived placebo effect is the response observed in the placebo treatment group of randomized controlled trials (RCTs), while the true placebo effect equals the perceived placebo effect minus other nonspecific effects that often determine the outcome not only in the placebo treatment group, but also in the active drug treatment group. It is recognized that RCTs assessing α~1~-adrenoceptor antagonists (α~1~ blockers) for lower urinary tract symptoms (LUTS) with benign prostatic hyperplasia (BPH) show high placebo responses of 9%--34%.[@b5-rru-5-083],[@b6-rru-5-083] On the other hand, nonspecific factors that play a role in other non-specific effects include natural course of disease, regression towards the mean, other time effects such as seasonal effect, and unidentified parallel interventions. In routine urologic practice, urologists are aware that cold ambient temperature as a nonspecific factor exacerbates LUTS with BPH irrespective of the administration of α~1~ blockers.

Naftopidil, a long-acting α~1~ blocker with a high affinity for α~1D~-adrenoceptors,[@b7-rru-5-083] is as effective and safe as tamsulosin,[@b8-rru-5-083]--[@b10-rru-5-083] although there are no placebo-controlled RCTs on naftopidil.[@b11-rru-5-083] Up to 1999, naftopidil was available in Japan under the brand names Avishot™ (Nippon Organon KK, Osaka, Japan) and Flivas™ (Asahi Kasei Pharma Corp, Tokyo, Japan). The two drugs contained the same principal ingredient and displayed the same pharmacokinetic properties.[@b12-rru-5-083] However, in 2008, Asahi Kasei Pharma Corp, acquired all intellectual property rights related to naftopidil. Thereafter, naftopidil has been sold only as Flivas™, and so BPH patients who wanted to continue with naftopidil had to switch from Avishot™ to Flivas™. Although the placebo effect on LUTS has been proven by RCTs,[@b5-rru-5-083],[@b6-rru-5-083] comparison of the data before and after switching from one brand of naftopidil to another at the same dose and timing would provide additional information as to the perceived placebo effect on LUTS with BPH.

We conducted a retrospective study on BPH patients to examine if switching from one brand of naftopidil to another at the same dose and timing causes the same changes in LUTS and quality of life (QOL) as the perceived placebo effect, and if ambient temperature is involved in those changes as a nonspecific factor.

Patients and methods
====================

A review of the medical records of the Jichi Medical University Hospital, Tochigi, Japan, showed that, between December 2008 and July 2009, 385 patients with BPH were switched from Avishot™ to Flivas™ (data on file from 2008--2009, Jichi Medical University Hospital). The present retrospective analysis covers 217 of these patients; the other 168 patients were excluded due to receiving other medications for BPH and/or not visiting the hospital or completing the questionnaire (described later) after switching drugs. Patient prostate size according to digital rectal examination ranged from large walnut size to small hen's egg size. All patients whose LUTS had remained stable under treatment with 50 mg/day or 75 mg/day of Avishot™ for more than 6 months were switched to Flivas™ at the same dose and timing. As naftopidil has been sold only as Flivas™ in Japan since 2008, BPH patients previously treated with Avishot™ who wanted to continue naftopidil treatment had to switch from Avishot™ to Flivas™ at that time.

Before and at 3 months after switching drugs, we evaluated the total International Prostate Symptom Score (IPSS); the scores of individual IPSS items; voiding symptoms (intermittency, weak urinary stream, abdominal straining to void), storage symptoms (nighttime frequency, daytime frequency, urgency); postvoiding symptom (incomplete emptying); and QOL score. Baseline characteristics of the patients are shown in [Table 1](#t1-rru-5-083){ref-type="table"}. The average monthly ambient temperatures in degrees Celsius (°C) at the patients' residence area (longitude 139°E, latitude 36°N, in a temperate zone) during the switch in drugs were obtained from the Automated Meteorological Data Acquisition System (AMeDAS), operated by the Japan Meteorological Agency (<http://www.jma.go.jp/jma/indexe.html>), and are shown in [Figure 1](#f1-rru-5-083){ref-type="fig"}. In the present study, perceived placebo effect was defined as any significant change of the parameters by switching drugs. The present study was approved by the institutional review board of Jichi Medical University and informed consent was obtained from all patients. The Mann--Whitney *U* test, Wilcoxon signed rank test, and Spearman rank correlations were used for statistical analysis, and *P*-values of less than 0.05 were considered statistically significant.

Results
=======

Changes in LUTS and QOL after switching drugs
---------------------------------------------

The changes in scores for IPSS items, voiding symptom score, storage symptom score, total IPSS, and QOL score after switching drugs are shown in [Figure 2](#f2-rru-5-083){ref-type="fig"}. Among the IPSS items, nighttime frequency decreased significantly (*P* \< 0.001), while daytime frequency tended to decrease (from 2.0 ± 1.4 to 1.8 ± 1.3; *P* = 0.097), resulting in the significant improvement of storage symptoms (*P* = 0.006). Furthermore, QOL scores tended to improve (from 3.0 ± 1.3 to 2.9 ± 1.3; *P* = 0.052). Thus, switching drugs improved the LUTS, especially the storage symptoms, suggesting the perceived placebo effect on LUTS because the two drugs contain the same principal ingredient and display the same pharmacokinetic properties, as described earlier.

Involvement of calendar-based seasons in perceived placebo effect after switching drugs
---------------------------------------------------------------------------------------

To examine the possible involvement of the calendar-based seasons in this perceived placebo effect, the patients were divided into eight groups according to the period from baseline to 3 months, as shown in [Table 2](#t2-rru-5-083){ref-type="table"}, since there are four seasons in Japan: spring (March, April, May), summer (June, July, August), fall (September, October, November), and winter (December, January, February). There was no significant difference in age, IPSS, and QOL score at baseline among the periods. In the period February--May, significant improvement was observed in total IPSS (*P* \< 0.05), scores for urgency (*P* \< 0.05), nighttime frequency (*P* \< 0.001), and storage symptoms (*P* \< 0.001). In March--June, significant improvement was observed in scores for nighttime frequency (*P* \< 0.01) and storage symptoms (*P* \< 0.05). In June--September, incomplete emptying deteriorated rather significantly (*P* \< 0.05). These results suggest that the nonspecific effect on LUTS in the perceived placebo effect, rather than the true placebo effect, is involved in the changes in LUTS after switching drugs. Since a clear seasonal change in LUTS/QOL was not observed, it can be concluded that the season was not involved in the nonspecific effect in the perceived placebo effect by switching drugs.

Involvement of ambient temperature in nonspecific effect
--------------------------------------------------------

We analyzed the association between the number of parameters with significant change ([Table 2](#t2-rru-5-083){ref-type="table"}) and the average monthly ambient temperature at 3 months ([Figure 1](#f1-rru-5-083){ref-type="fig"}) in each seasonal period to examine the possible involvement of ambient temperature in the nonspecific effect in the perceived placebo effect after switching drugs. For the statistical analysis, one significantly improved parameter was assigned as +1 while one significantly deteriorated parameter was assigned as −1. The results showed no significant association ([Figure 3](#f3-rru-5-083){ref-type="fig"}).

The patients were then divided into two groups according to the average monthly ambient temperature at 3 months in each period higher than 20°C (June, July, August, September) or lower than 20°C (March, April, May, October) ([Figure 1](#f1-rru-5-083){ref-type="fig"}), as the ambient temperature for human thermal comfort is higher than 18°C.[@b13-rru-5-083],[@b14-rru-5-083] There was no significant difference in IPSS and QOL score at baseline between the two groups (data not shown). In the former group, significant improvement was noted in nighttime frequency (*P* \< 0.05), while in the latter group, there was significant improvement of nighttime frequency (*P* \< 0.001) and storage symptoms (*P* \< 0.01) ([Figure 4](#f4-rru-5-083){ref-type="fig"}). The same analysis was performed for average monthly ambient temperature at baseline; the results were the same for those at 3 months (data not shown). Similar improvement of LUTS in both groups was observed, suggesting that the average monthly ambient temperature itself is not involved in the nonspecific effect on LUTS.

Involvement of magnitude of ambient temperature change in nonspecific effect
----------------------------------------------------------------------------

We analyzed the association between the number of parameters with significant change ([Table 2](#t2-rru-5-083){ref-type="table"}) and the magnitude of change in average monthly ambient temperature from baseline to 3 months ([Figure 5](#f5-rru-5-083){ref-type="fig"}) in each seasonal period to examine the possible involvement of the magnitude of change in average monthly ambient temperature in the nonspecific effect in the perceived placebo effect by switching drugs. For the statistical analysis, one significantly improved parameter was assigned as +1 while one significantly deteriorated parameter was assigned as −1. As shown in [Figure 6](#f6-rru-5-083){ref-type="fig"}, a significant association was observed (*P* = 0.0322); namely, the greater the magnitude of change in average monthly ambient temperature from baseline to 3 months, the greater the number of significant parameters in each period. We then divided the patients into two groups according to magnitude of change in average monthly ambient temperature from baseline to 3 months higher than 10°C (February--May, March--June, April--July) or lower than 10°C (December--March, January--April, May-- August, June--September, July--October) to have a similar number of patients in each group for the statistical analysis ([Figure 5](#f5-rru-5-083){ref-type="fig"}). There was no significant difference in IPSS and QOL score at the baseline between the two groups (data not shown). As shown in [Figure 7](#f7-rru-5-083){ref-type="fig"}, in the former group, there was significant improvement in daytime frequency (*P* \< 0.05), nighttime frequency (*P* \< 0.001), storage symptoms (*P* \< 0.001), and total IPSS (*P* \< 0.05). On the other hand, in the latter group, no significant improvement was noted in any of the parameters examined. The periods of February-- May and March--June in which significant improvement of LUTS was observed ([Table 2](#t2-rru-5-083){ref-type="table"}) were those with the two highest magnitudes of ambient temperature change among the periods ([Figure 5](#f5-rru-5-083){ref-type="fig"}). On the other hand, incomplete emptying deteriorated somewhat in the periods of June--September and July--October ([Table 2](#t2-rru-5-083){ref-type="table"}) when the magnitude of ambient temperature change was lower than 0°C ([Figure 5](#f5-rru-5-083){ref-type="fig"}). These results suggest that the magnitude of ambient temperature change is involved in the nonspecific effect in the perceived placebo effect by switching drugs.

Discussion
==========

The present study showed that switching from Avishot™ to Flivas™ induced significant changes in LUTS, especially in storage symptoms, suggesting the perceived placebo effect. These changes in LUTS after switching drugs would be due to the nonspecific effect in the perceived placebo effect rather than the true treatment effect of naftopidil or the switching of drugs itself because the extent of changes in LUTS was different among the periods when the drug was switched. In addition, the present study has shown for the first time that magnitude of ambient temperature change was a nonspecific factor that influences LUTS in BPH.

It is well known that cold temperature is a stress factor that can induce various physiological responses, such as increase in blood pressure;[@b15-rru-5-083],[@b16-rru-5-083] thus, cold temperature might affect bladder function, resulting in the change in LUTS. A questionnaire study showed that feeling colder or warmer is one of the reasons for nighttime frequency in BPH patients.[@b17-rru-5-083] In experimental rat studies, cold temperature is shown to enhance the activation of the hypothalamic--pituitary--adrenal axis[@b18-rru-5-083] and increase the secretion of urinary epinephrine,[@b19-rru-5-083] which is one of the neurotransmitters that could modulate LUTS.[@b20-rru-5-083],[@b21-rru-5-083] Furthermore, in experimental studies with conscious rats, a sudden drop in environmental temperature induced detrusor overactivity[@b22-rru-5-083],[@b23-rru-5-083] and partially changed the micturition pattern via α~1~-adrenoceptors.[@b23-rru-5-083] These reports support our results that storage symptoms were influenced by the nonspecific effect of the magnitude of ambient temperature change. Other factors, such as increased insensible water loss in warm and hot seasons, which leads to decreased urinary frequency as a result of decreased urine volume during nighttime, might be a factor in our results, although frequency--volume charts were not included in the present retrospective study.

Seasonal (summer versus winter) variation in LUTS has been investigated by means of a community-based questionnaire in three different climatic regions of Japan: subarctic (Hokkaido), temperate (Kyoto), and subtropical (Okinawa).[@b24-rru-5-083] Storage symptoms, including daytime frequency, nighttime frequency, and urgency, improved in summer compared to winter, or deteriorated in winter compared to summer; the magnitude of ambient temperature change between two seasons in three regions (summer and winter in subarctic, temperate, and subtropical regions) was higher than 10°C. Furthermore, this tendency was marked in the subtropical and temperate zones but was not observed in the subarctic zone, suggesting that the variation in storage symptoms depended on the region in which the study was performed. The present result that the magnitude of change in average monthly temperature higher than 10°C was involved in the variation in storage symptoms is consistent with the study described above,[@b24-rru-5-083] seemingly due, in part, to the fact that the present study was performed in the temperate zone. Considering that (1) nighttime frequency is an indoor event; (2) low ambient temperature does not always lead to variation in LUTS;[@b24-rru-5-083] (3) indoor temperature is affected not only by ambient temperature but by various other factors, such as type of heating and housing; and (4) a sudden drop in environmental temperature induces detrusor overactivity as shown by experimental animal studies,[@b22-rru-5-083],[@b23-rru-5-083] suggests that indoor temperature rather than ambient temperature might be appropriate as a nonspecific factor for LUTS at the individual level irrespective of the region. Further studies are needed to elucidate the involvement of indoor temperature in the variation of LUTS.

In routine urologic practice, urologists are aware that cold weather exacerbates LUTS with BPH irrespective of the administration of α~1~ blockers. The guideline by the Japanese Urological Association (JUA) recommends that males with LUTS avoid exposing the lower body to cold temperature.[@b25-rru-5-083] However, there is little high-quality evidence that provides reliable information on the influence of ambient temperature on LUTS in BPH patients.[@b25-rru-5-083]--[@b27-rru-5-083] Our results support the lifestyle advice "avoid exposing the lower body to cold temperature" or "keep warm when it is cold:"[@b25-rru-5-083] improvement of LUTS was observed when magnitude of ambient temperature change was higher than 10°C; incomplete emptying was worse in the periods of June--September and July--October ([Table 2](#t2-rru-5-083){ref-type="table"}) when the magnitude of ambient temperature change was lower than 0°C ([Figure 5](#f5-rru-5-083){ref-type="fig"}).

The present study raises important issues for the evaluation of clinical trials for BPH. Namely, the treatment effect could be overestimated if patients are enrolled in a cold season and evaluated in a warm season, while it could be underestimated if patients are enrolled in a warm season and evaluated in a cold season in short-term uncontrolled trials. In short-term, nonrandomized controlled trials, the difference in the distribution of entry timing in each group (control group or active drug treatment group) could lead to overestimation or underestimation of treatment effect. The same would be true in routine clinical practice. Thus, consideration must be given to the nonspecific effect by ambient temperature change when interpreting the changes in LUTS in those clinical trials and in routine clinical practice.

The limitations of the present study include the retrospective nature; relatively small number of patients examined; comparison of different populations in different periods, lack of frequency--volume charts; lack of four enrollment periods (August--November, September--December, October--January, November--February); and insufficient background information on the patients. Despite these limitations, the present study provides evidence that the nonspecific effect of magnitude of ambient temperature change was involved in the perceived placebo effect on LUTS, especially on storage symptoms, by switching drugs. The nonspecific effect on LUTS in BPH needs to be considered when evaluating subjective treatment efficacy of the drugs for LUTS in BPH in routine clinical practice. In addition, the present study supports the lifestyle advice "avoid exposing the lower body to cold temperature" or "keep warm when it is cold"[@b25-rru-5-083] for LUTS with BPH.
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![Average monthly ambient temperature around patients' residential area obtained from AMeDAS. Data is for Oyama city, Tochigi, Japan (longitude 139°E, latitude 36°N, in a temperate zone).\
**Abbreviation:** AMeDAS, automated meteorological data acquisition system.](rru-5-083Fig1){#f1-rru-5-083}

![Changes in IPSS and QOL score by switching drugs.\
**Notes:** (n = 217). Mean values were plotted for the total International Prostate Symptom Score (IPSS), the scores of individual IPSS items, voiding symptoms (intermittency, weak stream, straining), storage symptoms (daytime frequency, nighttime frequency, urgency), post-voiding symptom (incomplete emptying), and quality of life (QOL) score before and 3 months after switching drugs.\
\**P* \< 0.001, \*\**P* = 0.006 compared to the baseline by Wilcoxon signed rank test.](rru-5-083Fig2){#f2-rru-5-083}

![Association between number of parameters with significant change and average monthly ambient temperature at three months.\
**Notes:** The number of parameters with significant change shown in [Table 2](#t2-rru-5-083){ref-type="table"} was not associated with average monthly ambient temperature at three months ([Figure 1](#f1-rru-5-083){ref-type="fig"}) in each period by Spearman rank correlations (n = 217). For the statistical analysis, one significantly improved parameter was assigned as +1 while one significantly deteriorated parameter was assigned as −1.](rru-5-083Fig3){#f3-rru-5-083}

![Changes in IPSS and QOL score by average monthly ambient temperature at three months after switching drugs.\
**Notes:** Patients were divided into two groups according to the average monthly ambient temperature at 3 months in each period higher than 20°C (n = 98) or lower than 20°C (n = 119). Mean values were plotted for the total International Prostate Symptom Score (IPSS), the scores of individual IPSS items, voiding symptoms (intermittency, weak stream, straining), storage symptoms (daytime frequency, nighttime frequency, urgency), post-voiding symptom (incomplete emptying), and quality of life (QOL) score before and 3 months after switching drugs.\
\**P* \< 0.05, \*\**P* \< 0.01, ^§^*P* \< 0.001 compared to the baseline in each group by Wilcoxon signed rank test.](rru-5-083Fig4){#f4-rru-5-083}

![Magnitude of changes in average monthly ambient temperature from baseline to three months around patients' residential area obtained from AMeDAS.\
**Notes:** Magnitude of change in average monthly ambient temperature from baseline to 3 months in each period equals the average monthly ambient temperature at 2 months minus that at the baseline.\
**Abbreviation:** AMeDAS, automated meteorological data acquisition system.](rru-5-083Fig5){#f5-rru-5-083}

![Association between number of parameters with significant change and magnitude of changes in average monthly ambient temperature.\
**Notes:** The number of parameters with significant change shown in [Table 2](#t2-rru-5-083){ref-type="table"} was significantly associated with the magnitude of changes in average monthly ambient temperature from baseline to 3 months ([Figure 5](#f5-rru-5-083){ref-type="fig"}) in each period by Spearman rank correlation (*P* = 0.0322) (n = 217). For the statistical analysis, one significantly improved parameter was assigned as +1 while one significantly deteriorated parameter was assigned as −1.](rru-5-083Fig6){#f6-rru-5-083}

![Changes in IPSS and QOL score by magnitude of changes in average monthly ambient temperature from baseline to three months.\
**Notes:** Patients were divided into two groups according to magnitude of change in average monthly ambient temperature from baseline to 3 months higher than 10°C (n = 128) or lower than 10°C (n = 89). Magnitude of change in average monthly ambient temperature from baseline to 3 months in each period equals the average monthly ambient temperature at three months minus that at the baseline. Mean values were plotted for the total International Prostate Symptom Score (IPSS), the scores of individual IPSS items, voiding symptoms (intermittency, weak stream, straining), storage symptoms (daytime frequency, nighttime frequency, urgency), post-voiding symptom (incomplete emptying), and quality of life (QOL) score before and three months after switching drugs.\
\**P* \< 0.05, ^§^*P* \< 0.001 compared to the baseline in each group by Wilcoxon signed rank test.](rru-5-083Fig7){#f7-rru-5-083}

###### 

Baseline characteristics of study patients

  ---------------------------------- ------------
  Patients (n)                       217
  Age (years)                        74.3 ± 8.0
  IPSS[@b25-rru-5-083] items         
   Q1 incomplete emptying            1.3 ± 1.4
   Q2 daytime frequency              1.9 ± 1.4
   Q3 intermittency                  1.2 ± 1.5
   Q4 urgency                        1.3 ± 1.4
   Q5 weak stream                    2.1 ± 1.6
   Q6 straining                      1.0 ± 1.4
   Q7 nighttime frequency            2.3 ± 1.2
  Voiding symptom score (Q2, 4, 7)   4.3 ± 3.6
  Storage symptom score (Q3, 5, 6)   5.5 ± 3.1
  Total IPSS                         11.2 ± 6.7
  QOL score                          3.0 ± 1.3
  ---------------------------------- ------------

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** IPSS, International Prostate Symptom Score; Q, question; QOL, quality of life.

###### 

Changes in IPSS and QOL scores from baseline to 3 months, according to seasonal period

                                     Seasonal period from baseline to 3 months                                                                                                                                                                                                                                                                         
  ---------------------------------- ------------------------------------------- ----------------------- --------------------------------------------------------------- -------------------------------------------------------------- ----------------------- ----------------------- -------------------------------------------------------------- --------------------------------------------------------------
  Patients (n)                       2                                           29                      76                                                              23                                                             29                      23                      23                                                             12
  Age (years)                        79.5 ± 5.0                                  74.6 ± 8.6              73.2 ± 7.2                                                      76.0 ± 8.3                                                     73.6 ± 8.3              76.0 ± 9.1              75.0 ± 8.8                                                     73.3 ± 6.7
  IPSS items                                                                                                                                                                                                                                                                                                                                           
   Q1 incomplete emptying            1.0 ± 0.0/0.0 ± 0.0^a^                      1.3 ± 1.4/1.3 ± 1.5     1.2 ± 1.4/1.2 ± 1.4                                             1.4 ± 1.5/1.2 ± 1.1                                            1.6 ± 1.6/1.3 ± 1.6     1.6 ± 1.3/1.2 ± 1.2     1.4 ± 1.3/1.9 ± 1.6[b](#tfn4-rru-5-083){ref-type="table-fn"}   1.0 ± 1.0/1.7 ± 1.2[b](#tfn4-rru-5-083){ref-type="table-fn"}
   Q2 daytime frequency              3.0 ± 2.8/1.5 ± 0.7                         1.7 ± 1.5/1.8 ± 1.4     1.8 ± 1.3/1.6 ± 1.0                                             1.8 ± 1.4/1.4 ± 1.3                                            2.4 ± 1.7/2.4 ± 1.5     2.3 ± 1.1/2.2 ± 1.3     1.8 ± 1.6/1.9 ± 1.4                                            1.8 ± 1.6/1.4 ± 1.2
   Q3 intermittency                  4.0 ± 1.4/2.5 ± 3.5                         1.0 ± 1.5/1.2 ± 1.6     1.1 ± 1.4/1.2 ± 1.7                                             1.2 ± 1.3/0.9 ± 1.1                                            1.6 ± 1.5/1.9 ± 1.5     1.0 ± 1.1/1.3 ± 1.5     1.5 ± 1.5/1.7 ± 1.7                                            1.4 ± 2.0/1.7 ± 1.9
   Q4 urgency                        2.0 ± 1.4/1.0 ± 1.4                         1.3 ± 1.3/1.4 ± 1.7     1.3 ± 1.5/1.0 ± 1.3[b](#tfn4-rru-5-083){ref-type="table-fn"}    1.3 ± 1.3/1.2 ± 1.4                                            1.3 ± 1.5/1.7 ± 1.7     1.7 ± 1.5/1.8 ± 1.5     1.4 ± 1.6/1.4 ± 1.6                                            0.8 ± 0.7/1.3 ± 1.4
   Q5 weak stream                    3.5 ± 2.1/5.0 ± 0.0                         2.1 ± 1.6/1.8 ± 1.8     1.9 ± 1.6/1.7 ± 1.8                                             2.1 ± 1.4/1.8 ± 1.5                                            2.6 ± 1.8/2.5 ± 1.9     2.1 ± 1.1/2.6 ± 1.6     2.0 ± 1.6/2.4 ± 1.9                                            1.9 ± 1.7/1.8 ± 1.8
   Q6 straining                      2.5 ± 3.5/2.5 ± 3.5                         0.7 ± 1.4/1.0 ± 1.5     0.9 ± 1.5/0.8 ± 1.3                                             1.0 ± 1.2/1.0 ± 1.4                                            1.1 ± 1.3/1.5 ± 1.5     0.9 ± 1.1/1.0 ± 1.3     1.4 ± 1.6/1.4 ± 1.5                                            1.0 ± 1.6/0.8 ± 1.5
   Q7 nighttime frequency            3.0 ± 1.4/2.5 ± 2.1                         2.5 ± 1.1/2.4 ± 1.1     2.3 ± 1.2/1.9 ± 1.1[d](#tfn6-rru-5-083){ref-type="table-fn"}    2.1 ± 1.0/1.7 ± 0.9[c](#tfn5-rru-5-083){ref-type="table-fn"}   2.3 ± 1.4/2.2 ± 1.3     2.1 ± 1.0/2.0 ± 1.1     2.3 ± 1.1/2.2 ± 1.3                                            1.8 ± 0.9/2.1 ± 1.2
  Voiding symptom score (Q2, 4, 7)   10.0 ± 7.1/10.0 ± 7.1                       3.9 ± 3.5/4.0 ± 4.2     3.8 ± 3.7/3.7 ± 3.7                                             4.3 ± 2.9/3.7 ± 3.4                                            5.3 ± 3.5/5.9 ± 4.3     4.0 ± 2.1/4.9 ± 3.4     4.9 ± 4.1/5.5 ± 4.5                                            4.3 ± 4.7/4.3 ± 4.2
  Storage symptom score (Q3, 5, 6)   8.0 ± 2.8/5.0 ± 4.2                         5.5 ± 2.8/5.6 ± 3.1     5.4 ± 3.1/4.5 ± 2.5[d](#tfn6-rru-5-083){ref-type="table-fn"}    5.2 ± 2.9/4.3 ± 2.9[b](#tfn4-rru-5-083){ref-type="table-fn"}   6.1 ± 3.8/6.3 ± 3.8     6.1 ± 2.7/6.0 ± 2.9     5.5 ± 3.3/5.6 ± 3.3                                            4.5 ± 2.3/4.7 ± 2.6
  Total IPSS                         19.0 ± 9.9/15.0 ± 11.3                      10.7 ± 6.5/10.9 ± 7.8   10.4 ± 6.6/9.4 ± 6.4[b](#tfn4-rru-5-083){ref-type="table-fn"}   10.9 ± 6.4/9.1 ± 6.0                                           13.0 ± 7.1/13.5 ± 7.3   11.7 ± 4.4/12.0 ± 5.4   11.7 ± 7.8/12.9 ± 8.0                                          9.6 ± 7.9/10.5 ± 7.1
  QOL score                          3.0 ± 0.0/3.0 ± 0.0                         3.2 ± 1.3/3.1 ± 1.4     3.0 ± 1.4/2.9 ± 1.3                                             2.7 ± 1.5/2.4 ± 0.9                                            3.1 ± 1.0/3.1 ± 1.2     3.1 ± 1.3/3.0 ± 1.4     3.2 ± 1.3/2.8 ± 1.5                                            2.8 ± 1.3/2.4 ± 1.3

**Notes:** Data are presented as mean + standard deviation.

Score at baseline/score at 3 months;

*P* \< 0.05;

*P* \< 0.01;

*P* \< 0.001 compared to the baseline by Wilcoxon signed rank test.

**Abbreviations:** IPSS, International Prostate Symptom Score; Q, question; QOL, quality of life.
